$11.00 $0.30 (2.8%)

04:00 PM EST on 11/13/19

AnaptysBio, Inc. (NASDAQ:ANAB)

CAPS Rating: 3 out of 5

Current Price $11.00 Mkt Cap $290.3M
Open $10.68 P/E Ratio 0.00
Prev. Close $10.70 Div. (Yield) $0.00 (0.0%)
Daily Range $10.45 - $11.69 Volume 2,193,493
52-Wk Range $10.00 - $83.10 Avg. Daily Vol. 942,951

Caps

How do you think NASDAQ:ANAB will perform against the market?

Add Stock to CAPS Watchlist

All Players

31 Outperform
2 Underperform
 

All-Star Players

7 Outperform
0 Underperform
 

Wall Street

0 Outperform
0 Underperform
 

Top NASDAQ:ANAB Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

Top Bull Pitch

There are no pitches that meet the Top Bull criteria. Explain

If this upsets you, start recommending pitches below!

Top Bear Pitch

There are no pitches that meet the Top Bear criteria. Explain

If this upsets you, start recommending pitches below!

NASDAQ:ANAB VS S&P 500 (SPY)

NASDAQ:ANAB Summary

Fools bullish on NASDAQ:ANAB are also bullish on:

Fools bearish on NASDAQ:ANAB are also bearish on:

Recent Community Commentary

Read the most recent pitches from players about ANAB.

Recs

0
Member Avatar oscillation (69.55) Submitted: 11/9/2019 3:37:02 PM : Outperform Start Price: $10.40 NASDAQ:ANAB Score: +5.27

nev

Recs

0
Member Avatar Bigsef77 (68.17) Submitted: 9/24/2018 1:01:23 PM : Outperform Start Price: $117.36 NASDAQ:ANAB Score: -100.57

Here's Why AnaptysBio Inc Rose as Much as 18.5% Today

Shares of AnaptysBio (NASDAQ: ANAB) rose over 18% after the company announced positive top-line data from an ongoing phase 2a trial investigating the potential of its lead drug candidate to treat a severe form of asthma. The therapeutic antibody, etokimab, demonstrated promise in treating severe eosinophilic asthma, which is characterized by severe inflammation and restriction of air pathways in an individual's lungs.

The day after receiving a single dose of etokimab, patients averaged an 8% increase in a measure of lung capacity called forced exhaled volume in one second (FEV1) compared to placebo. That advantage increased to an average improvement of 11% on day 64 of the ongoing trial. No serious adverse events were reported, hinting that the drug candidate is well tolerated.

As of 12:22 p.m. EDT, the stock had settled to a 8.4% gain.

Recs

0
Member Avatar TurksFan (41.36) Submitted: 4/7/2018 8:43:26 AM : Outperform Start Price: $85.86 NASDAQ:ANAB Score: -105.46

Starting my research into biotechs

Leaderboard

Find the members with the highest scoring picks in ANAB.

Score Leader

mrmrmrj

mrmrmrj (51.77) Score: +240.40

The Score Leader is the player with the highest score across all their picks in ANAB.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
darrellquock 78.49 8/16/2019 Underperform 5Y $51.31 -78.56% +7.84% +86.40 0 Comment
oscillation 69.55 11/11/2019 Outperform 5Y $10.40 +5.82% +0.55% +5.27 1 Comment
tilolo76 < 20 11/8/2019 Outperform 5Y $10.91 +0.82% +0.25% +0.58 0 Comment
Playa14 < 20 11/8/2019 Outperform 5Y $10.91 +0.82% +0.35% +0.47 0 Comment
Bigcaps19 75.41 11/8/2019 Underperform 5Y $10.91 +0.82% +0.36% -0.47 0 Comment
scbydo69 41.56 10/1/2019 Outperform 5Y $30.88 -64.37% +3.76% -68.13 0 Comment
mrmrmrj 51.77 11/1/2019 Outperform 5Y $38.87 -71.70% +1.09% -72.79 0 Comment
flighttofreedom 73.85 8/22/2019 Outperform 5Y $42.52 -74.13% +6.27% -80.40 0 Comment
jcder 27.10 4/5/2019 Outperform 5Y $78.47 -85.98% +7.36% -93.35 0 Comment
RPMick 86.55 8/30/2018 Outperform 1Y $87.33 -87.40% +6.25% -93.65 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for ANAB.